Premaitha signs exclusive Russian distribution agreement for its flagship IONA test

Premaitha signs exclusive Russian distribution agreement for its flagship IONA test

Manchester-based medical diagnostics company Premaitha Health has signed an exclusive Russia distribution agreement for its flagship IONA test – the CE marked non-invasive prenatal screening test.

The deal has been struck with GeNext LLC, a company dedicated to providing high quality molecular diagnostic products and will open up a key new market for Premaitha.

“We are delighted to have signed this agreement with GeNext to provide the IONA test in Russia,” said Premaitha chief executive Dr Stephen Little. This is a new territory for Premaitha and it enables us to establish a local laboratory offering routine non-invasive prenatal screening. With the signing of this latest agreement, Premaitha is demonstrating its ability to develop a network of partners servicing many countries across the globe.”

GeNext chief executive Vitali Proutski said: “This is an extremely important alliance for GeNext, as there is compelling clinical evidence to support the benefits of NIPT, and we believe Premaitha’s IONA system is the market leading product. We have built up significant expertise in the distribution of molecular diagnostics and the inclusion of the IONA® test within our portfolio will significantly enhance our offering.”

The deal follows other major breakthroughs for the IONA test, including deals to offer the service in Eastern Europe and India and the recommendation by the UK’s National Screening Committee that the test should be routinely offered to the NHS.

See the article in full at

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.